Investors Buy Large Volume of Dynavax Technologies Put Options (DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX) was the target of some unusual options trading on Monday. Stock traders purchased 2,440 put options on the company. This is an increase of 1,352% compared to the typical volume of 168 put options.

In other news, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total transaction of $141,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $18.60, for a total value of $57,511.20. Following the transaction, the vice president now owns 7,780 shares of the company’s stock, valued at $144,708. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Fox Run Management L.L.C. acquired a new position in Dynavax Technologies in the 4th quarter valued at $257,000. Schwab Charles Investment Management Inc. grew its holdings in shares of Dynavax Technologies by 17.5% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 276,430 shares of the biopharmaceutical company’s stock worth $5,170,000 after purchasing an additional 41,120 shares in the last quarter. Creative Planning grew its holdings in shares of Dynavax Technologies by 52.1% during the 4th quarter. Creative Planning now owns 230,848 shares of the biopharmaceutical company’s stock worth $4,317,000 after purchasing an additional 79,025 shares in the last quarter. Vident Investment Advisory LLC grew its holdings in shares of Dynavax Technologies by 3.1% during the 3rd quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after purchasing an additional 4,553 shares in the last quarter. Finally, First Republic Investment Management Inc. acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth $2,414,000. 70.54% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on the company. BidaskClub cut Dynavax Technologies from a “sell” rating to a “strong sell” rating in a report on Friday. Zacks Investment Research cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Cantor Fitzgerald boosted their target price on Dynavax Technologies from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Thursday, November 9th. Finally, Cowen restated a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. Dynavax Technologies currently has an average rating of “Hold” and a consensus price target of $25.17.

Dynavax Technologies (DVAX) opened at $15.65 on Friday. The firm has a market capitalization of $934.70, a P/E ratio of -8.03 and a beta of 1.31. Dynavax Technologies has a 1-year low of $3.70 and a 1-year high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 51.46% and a negative net margin of 41,750.95%. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. During the same period in the prior year, the firm posted ($0.90) EPS. The company’s revenue for the quarter was down 68.8% on a year-over-year basis. equities research analysts anticipate that Dynavax Technologies will post -1.72 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Investors Buy Large Volume of Dynavax Technologies Put Options (DVAX)” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://weekherald.com/2018/01/20/dynavax-technologies-target-of-unusually-high-options-trading-dvax.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply